<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757129</url>
  </required_header>
  <id_info>
    <org_study_id>JSSRMYY-HB-2</org_study_id>
    <nct_id>NCT04757129</nct_id>
  </id_info>
  <brief_title>Changes of Cardiopulmonary Function After Thrombolysis in Patients With Pulmonary Embolism</brief_title>
  <acronym>CCFATAPE</acronym>
  <official_title>Dynamic Changes of Circulatory and Respiratory Function After Thrombolysis in Patients With Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bin He</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators expect to enroll 50 acute pulmonary embolism patients treated with&#xD;
      thrombolysis in two hospitals. Dynamic changes of cardiopulmonary function after thrombolysis&#xD;
      are detected to evaluate which indicators can quickly reflect the effectiveness of&#xD;
      thrombolysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 50 acute pulmonary embolism(APE) patients treated with thrombolysis are enrolled in the&#xD;
      First Affiliated Hospital with Nanjing Medical University and Nanjing Drum Town Hospital from&#xD;
      January 1, 2020, to December 31, 2021. According to the 2019 ESC guideline, the standards for&#xD;
      thrombolysis in APE patients are as follows: within 2 weeks of onset; high-risk pulmonary&#xD;
      embolism; medium-high-risk pulmonary embolism with symptoms of aggravation.&#xD;
&#xD;
      Investigators dynamically monitor cardiopulmonary function of participants after&#xD;
      thrombolysis, including blood pressure, heart rate, respiratory rate, blood gas analysis,&#xD;
      2-dimensional echocardiography (left and right ventricular diameter, pulmonary artery&#xD;
      pressure, interventricular septum) and laboratory tests (cTnT,pro-BNP).participants are&#xD;
      divided into two groups: thrombolytic success group and thrombolytic failure group according&#xD;
      the previously reported criterion which is evaluated 48h after thrombolysis.&#xD;
&#xD;
      Cardiopulmonary characteristics are analyzed to seek accurate and rapid index to reflect&#xD;
      success of thrombolysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cardiopulmonary function changes</measure>
    <time_frame>48 hours after thrombolysis</time_frame>
    <description>changes of PO2，SBP，HR, cardiac ultrasound index and vasoactive drug dosage</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>thrombolysis success group</arm_group_label>
    <description>Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>thrombolysis failure group</arm_group_label>
    <description>Echocardiography was performed 48 hours after thrombolysis to evaluate the success of thrombolysis according to previous report.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        medium-high risk or high risk pulmonary embolism and treated with thrombolysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  medium-high risk or high risk pulmonary embolism and treated with thrombolysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lack of radiologic evidence to diagnose APE&#xD;
&#xD;
          -  death within 48 hours after thrombolytic therapy&#xD;
&#xD;
          -  unable to partner treatment and leaving hospitals&#xD;
&#xD;
          -  missing other necessary data&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bin He, Master</last_name>
    <phone>13770789159</phone>
    <email>hbhbwywy34@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin He, Master</last_name>
      <phone>13770789159</phone>
      <email>hbhbwywy34@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 14, 2021</last_update_submitted>
  <last_update_submitted_qc>February 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Bin He</investigator_full_name>
    <investigator_title>Attending physician of Affiliated Hospital of Nanjing Medical University</investigator_title>
  </responsible_party>
  <keyword>acute pulmonary embolism</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>Alteplase</keyword>
  <keyword>cardiopulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

